


ALCOMET FORUM 2026

Alcohol and Metabolic Liver Disease
Therapeutics Forum



ALCOMET Forum 2026

Alcohol and Metabolic Liver Disease Therapeutics Forum

Tagline: *Advancing biomarkers and therapeutics in alcohol-related liver disease (ALD) and metabolic- and alcohol-related liver disease (MetALD), across the disease spectrum from fibrosis to decompensated cirrhosis.*

Venue: Nyborg Strand, Nyborg, Denmark

Address: Oesteroevej 2, DK-5800 Nyborg, Denmark

Dates: June 21–24, 2026

Editorial

It is our great pleasure to announce the ALCOMET Forum 2026: Alcohol and Metabolic Liver Disease Therapeutics Forum, to be held June 21 – 24, 2026, in Nyborg, Denmark.

This international, in-person scientific meeting is dedicated to advancing therapeutic development and biomarker qualification in alcohol-related liver disease (ALD) and metabolic- and alcohol-related liver disease (MetALD). These conditions represent a growing global health burden and remain areas of major unmet medical need, with limited approved therapies and substantial challenges in clinical trial design and regulatory pathways.

The programme will bring together leading experts from academia, clinical research, regulatory authorities, and industry to address key issues, including endpoint selection, biomarker validation, alcohol consumption assessment, and the feasibility of global trials. Through plenary sessions and expert discussions, the meeting aims to define actionable strategies to accelerate drug development across the disease spectrum.

A key outcome of the meeting will be the ALCOMET 2026 Road Map Paper, outlining consensus priorities and a roadmap for the coming five years.

We look forward to welcoming you in Nyborg.

Aleksander Krag, MD, PhD

On behalf of the ALCOMET Forum 2026 Organising Committee

Programme at glance

Day 1 – The Therapeutic Landscape, Drug Targets and Learnings so far

Day 1 will focus on defining the current state of the field and identifying key translational and clinical development challenges across disease stages. Sessions will address:

- Global epidemiology and disease burden
- Current and emerging therapeutic pipelines
- Clinical trial design across fibrosis, compensated advanced chronic liver disease, decompensated cirrhosis, and alcohol-related hepatitis
- Translational insights from preclinical models
- Structured dialogue among academia, industry, and regulatory stakeholders

Day 2 – Clinical Trial Design, Recruitment, Research Agenda and Future Pathways

Day 2 will focus on enabling tools and regulatory considerations that are critical to accelerate therapeutic progress. Sessions will address:

- Biomarker development and qualification, including fibrosis markers and multi-omics approaches
- Integration of alcohol consumption assessment into clinical trials
- Lessons learned from the MASH field
- Patient recruitment strategies in global trials
- Regulatory perspectives and approval pathways

Organising committee

KRAG Aleksander
LEE Brian

MELLINGER Jessica
ISRAELSEN Mads

Scientific advisory board:

ARAB Juan Pablo
MORENO Christophe
SINGAL Ashwani

Faculty

ABRALDES Juan Gonzales

Professor, University of Alberta,
MD, PhD

ARAB Juan Pablo

Director of Alcohol Sciences,
Virginia Commonwealth
University, MD, PhD

ASKGAARD Gro

Associate Professor, Zealand
University Hospital, MD, PhD

BATALLER Ramon

Chair of Liver Unit Hospital Clínic of
Barcelona, MD, PhD

BRENNAN Paul

Associate Professor, University of
Dundee, MD, PhD

DIAZ Luis Antonio

Assistant Professor, University of
California San Diego, MD, PhD

FRANCQUE Sven

Professor, Antwerp University
Hospital and University, MD, PhD

GERMANI Giacomo

Professor, Padua University
Hospital, MD, PhD

GOMES RODRIGUES Susana

Senior Physician, University of
Bern, MD, PhD

HANSEN Camilla Dalby

Head of Daily Operations,
Odense University Hospital, MD,
PhD

ISRAELSEN Mads

Associate Professor, Odense
University Hospital, MD, PhD

JEPSEN Peter

Professor, Aarhus University
Hospital, MD, PhD

KARSDAL Morten

Professor and CEO, Nordic
Bioscience, MBA, PhD

KRAG Aleksander

Professor, Odense University
Hospital, MD, PhD, MBA

LEE Brian

Associate Professor of Medicine,
University of Southern California,
MD, PhD

LACKNER Carolin

Professor, Medical University of
Graz, MD, PhD

LONG Michelle

International Medical Vice
President, MASH, Novo Nordisk,
MS, MSc

LOUVET Alexandre

Professor, University of
Lille, MD, PhD

MANDORFER Mattias

Associate Professor, Medical
University of Vienna, MD, PhD

MARJOT Thomas

Clinical Senior Lecturer &
Consultant Hepatologist, King's
College London, MD, PhD

MEHTA Gautam

Associate Professor, University
College London Institute for Liver
and Digestive Health, MD, PhD

MELLINGER Jessica

Associate Professor, Henry Ford
Health, MD, PhD

MITCHELL Mack

Professor, University of Texas
Southwestern Medical Center,
MD, PhD

MORENO Christophe

Professor, Hôpital Universitaire de
Bruxelles, MD, PhD

NOURREDDIN Mazen

Professor, Houston Methodist
Hospital, MD, PhD

PARKER Richard

Associate Professor, University of
Leeds, MD, PhD

POSE Elisa

Senior Specialist, Hospital
Clínic Barcelona, MD, PhD

RINELLA Mary

Professor, University of Chicago,
MD, PhD

SCHNEIDER Carolin

Professor, RWTH Aachen
University, MD, PhD

SINGAL Ashwani

Professor, University of Louisville,
MD, PhD

STEFANESCU Horia

Senior Hepatologist, Cluj-Napoca,
MD, PhD

STENDER Stefan

Associate Professor,
Rigshospitalet, Copenhagen
University Hospital, MD, PhD

TACKE Frank

Professor, Charité,
Universitätsmedizin Berlin, MD,
PhD

THIELE Maja

Chief Scientific Officer, Evidio,
MD, PhD

TORP Nikolaj

Postdoctoral Researcher, Odense
University Hospital, MD, PhD

TSOCHATZIS Emmanuel

Professor, University College
London Institute for Liver and
Digestive Health, MD, PhD

VERGIS Nikhil

Clinical Lead Hepatology, GSK,
MD, PhD

WINDER Gerald Scott

Professor, Henry Ford Health,
MD, PhD

YOUNOSSI Zobair

Professor, Georgetown
University, MD, PhD

Coordinators**HANSEN Johanne Kragh**

Head of Daily Operations,
Odense University Hospital, MD, PhD

THORHAUGE Katrine

Postdoctoral Researcher,
Odense University Hospital, MD, PhD

VILLESEN Ida

Postdoctoral Researcher,
Odense University Hospital, MSc, PhD

ALCOMET 2026 Road Map paper working groups

- *Global epidemiology of patients in need for therapy*, Chair: JEPSEN Peter
- *Current status of drug development in ALD and MetALD*, Chair: LEE Brian
- *Learnings from the MASH field*, Chair: BRENNAN Paul
- *Drug targets and development strategies – Part I: Pathophysiology and drug targets*, Chair: POSE Elisa
- *Drug targets and development strategies – Part II: Preclinical models*, Chair: SCHNEIDER Carolin
- *Industry and regulatory perspectives*, Chair: KRAG Aleksander
- *Clinical trial design – Part I: Population*, Chair: LOUVET Alexandre
- *Clinical trial design – Part II: Alcohol quantification*, Chair: ISRAELSEN Mads
- *Clinical trial design – Part III: Endpoints*, Chair: MANDORFER Mattias
- *Clinical trials across the disease spectrum*, Chair: STEFANESCU Horia
- *Patient recruitment in global trials*, Chair: MARJOT Thomas

Sponsored by



**Boehringer Ingelheim,
Echosens, Kriya Therapeutics**

Programme

June 21 – Arrival Day

15.00 – 16.00: *Arrival and registration*

16.30 – 18.00: *Introduction to the ALCOMET 2026 Road Map Paper, KRAG Aleksander and ISRAELSEN Mads – working group meetings*

18.30: **Welcome dinner**

June 22 – Day 1: The Therapeutic Landscape, Drug Targets and Learnings so far

08.30 – 08.45: *Welcome and opening remarks, KRAG Aleksander, ISRAELSEN Mads*

08.45 – 09.00: *The urgent need for therapeutics in ALD and MetALD, KRAG Aleksander*

09.00 – 10.00 Session 1: Global Epidemiology of Patients in Need for Therapy

Chairs: JEPSEN Peter, LEE Brian

09.00 – 09.10: *Burden of alcohol-related liver disease, YOUNOSSI Zobair*

09.10 – 09.20: *The impact of alcohol underreporting, ISRAELSEN Mads*

09.20 – 09.30: *The interaction between alcohol and cardiometabolic risk factors, DIAZ Luis Antonio*

09.30 – 10.00: *Panel discussion – knowledge gaps and research agenda*

Moderator: JEPSEN Peter

Panel: LEE Brian, YOUNOSSI Zobair, ISRAELSEN Mads, DIAZ Luis Antonio

10.00 – 10.30: **Coffee break**

10.30 – 11.30 Session 2: Current Status of Drug Development in ALD and MetALD

Chairs: LEE Brian, Krag Aleksander

10.30 – 10.40: *Overview of investigator-initiated trials*, GOMES RODRIGUES Susana

10.40 – 10.50: *ALD 7730 Novo Nordisk*, LONG Michelle

10.50 – 11.00: *Considerations for Phase 2 studies in ALD from a sponsor's perspective: Experience from initiating the GSK STARLIGHT study*, VERGIS Nikhil

11.00 – 11.30: *Panel discussion – barriers and research agenda*

Moderator: Krag Aleksander

Panel: LEE Brian, GOMES RODRIGUES Susana, LONG Michelle, VERGIS Nikhil

11.30-12.00

12.00 – 13.00 Session 3: Learnings from the MASH Field

Chairs: BRENNAN Paul, FRANCQUE Sven

12.00 – 12.10: *Building a clinical trial network*, NOURREDDIN Mazen

12.10 – 12.20: *Endpoints – from early response biomarkers to surrogate endpoints for regulatory approval*, FRANCQUE Sven

12.20 – 12.30: *Sponsor perspectives: Key barriers in drug development for ALD and MetALD*, RINELLA Maru

12.30 – 13.00: *Panel discussion – barriers and research agenda*

Moderator: BRENNAN Paul

Panel: FRANCQUE Sven, NOURREDDIN Mazen, RINELLA Maru

13.00 – 14.00: Lunch

14.00 – 16.00 Session 4: Drug Targets and Development Strategies

14.00 – 15.00 Part I: Pathophysiology and Drug Targets

Chair: POSE Elisa

14.00 – 14.10: *Pathophysiology in ALD – drug targets*, PARKER Richard

14.10 – 14.20: *Genetics as drug targets*, STENDER Stefan

14.20 – 14.30: *Risk factors as drug targets - targeting alcohol use disorder and cardiometabolic diseases*, BATALLER Ramon

14.30 – 15.00: *Panel discussion – barriers and research agenda*

Moderator: POSE Elisa

Panel: PARKER Richard, STENDER Stefan, BATALLER Ramon

15.00 – 15.15: Break

15.15 – 16.00: Part II: Preclinical Models

Chairs: BATALLER Ramon

15.15 – 15.25: *In vivo models*, TACKE Frank

15.25 – 15.35: *Omics and AI models*, SCHNEIDER Carolin

15.35 – 16.00: *Panel discussion – barriers and research agenda*

Moderator: BATALLER Ramon

Panel: BATALLER Ramon, TACKE Frank, SCHNEIDER Carolin

16.00 – 16.30: Coffee break

16.30 – 17.30 Session 5: Industry and Regulatory Perspectives

Chairs: KRAG Aleksander, ARAB Juan Pablo

16.30 – 16.40: *Perspective on recruitment - industry representative*, VERGIS Nikhil

16.40 – 16.50: *Perspective on industry guidance for regulators*, LONG Michelle

16.50 – 17.00: *Regulatory perspective*, MITCHELL Mack

17.00 – 17.30: *Panel discussion – barriers and research agenda*

Moderator: KRAG Aleksander

Panel: ARAB Juan Pablo, VERGIS Nikhil, LONG Michelle, MITCHELL Mack

17.30 – 17.40: Closing remarks, KRAG Aleksander

19.00: Dinner

June 23 – Day 2: Clinical Trial Design, Recruitment, Research Agenda and Future Pathways

09.00 – 13.00 Session 6: Clinical Trial Design

09.00 – 10.00 Part I: Population

Chair: LOUVET Alexandre

09.00 – 09.10: *Populations in need of therapy – from early ALD to cirrhosis*, LOUVET Alexandre

09.10 – 09.20: *Pathways to identify patients in need of therapy*, TSOCHATZIS Emmanuel

09.20 – 09.40: *Debate: If abstinence works, why develop drugs for ALD?*

Pro: SINGAL Ashwani

Con: MELLINGER Jessica

09.40 – 10.00: *Panel discussion – barriers and research agenda*

Moderator: LOUVET Alexandre

Panel: TSOCHATZIS Emmanuel, SINGAL Ashwani, MELLINGER Jessica

10.00 - 11.00 Part II: Alcohol Quantification

Chairs: MARJOT Thomas, ISRAELSEN Mads

10.00 – 10.10: *Estimation of alcohol intake: Questionnaires*, LEE Brian

10.10 – 10.20: *Phosphatidyl ethanol (PEth) and other alcohol biomarkers*, TORP Nikolaj

10.20 – 10.40: *Debate: What should be the primary data source for alcohol intake: self-report or biomarkers?*

Self-reported: WINDER Gerald Scott

Biomarkers: RINELLA Maru

Moderator: MARJOT Thomas

10.40 – 11.00: *Panel discussion – barriers and research agenda*

Moderator: MARJOT Thomas

Panel: ISRAELSEN Mads, LEE Brian, TORP Nikolaj, RINELLA Maru, WINDER Gerald Scott

11.00 – 11:30: Break

11.30 – 13.00 Part III: ENDPOINTS

Chairs: MANDORFER Mattias, TSOCHATZIS Emmanuel

11.30 – 11.40: *From early response biomarkers to surrogate endpoints for regulatory approval*, KARSDAL Morten

11.40 – 11.50: *Imaging-based biomarkers of treatment response*, THIELE Maja

11.50 – 12.00: *Blood-based biomarkers of treatment response*, POSE Elisa

12.00 – 12.10: *Ordinal outcomes*, ABRALDES Juan Gonzales

12.10 – 12.20: *Histopathology: Endpoint validation and insights into mode of action*,
LACKNER Carolin

12.20 – 13.00: *Panel discussion – barriers and research agenda*

Moderator: MANDORFER Mattias

Panel: TSOCHATZIS Emmanuel, KARSDAL Morten, THIELE Maja, POSE Elisa, ABRALDES Juan Gonzales, LACKNER Carolin

13.00 – 14.00: Lunch

14.00 – 14.20: Keynote Lecture

14.00 – 14.10: *A global Delphi consensus to define chronic liver disease severity: Replacing cirrhosis with a stage-based model*, KRAG Aleksander

14.10 – 14.20: *Panel discussion – barriers and research agenda*

Moderator: MANDORFER Mattias

Panel: KRAG Aleksander, TSOCHATZIS Emmanuel, RINELLA Maru

14.20 – 15.20 Session 7: Clinical Trials Across the Disease Spectrum

Chairs: STEFANESCU Horia, MORENO Christophe

14.20 – 14.30: *Trials in pre-cirrhosis*, SINGAL Ashwani

14.30 – 14.40: *Trials in compensated advanced chronic liver disease (cACLD), with and without portal hypertension*, GERMANI Giacomo

14.40 – 14.50: *Trials in decompensated cirrhosis*, MORENO Christophe

14.50 – 15.00: *Status on EASL-AASLD statements on endpoints for clinical trials in MetALD and ALD*, ARAB Juan Pablo

15.00 – 15.20: *Panel discussion – barriers and research agenda*

Moderator: STEFANESCU Horia

Panel: SINGAL Ashwani, GERMANI Giacomo, MORENO Christophe, ARAB Juan Pablo

15.20 – 15.40: Break

15.40 – 16.30 Session 8: Patient Recruitment in Global Trials

Chairs: MARJOT Thomas, MEHTA Gautam

15.40 – 15.50: *Healthcare pathways*, MEHTA Gautam

15.50 – 16.00: *Patient identification and recruitment*, HANSEN Camilla Dalby

16.00 – 16.10: *Alcohol use disorder as a comorbidity*, ASKGAARD Gro

16.10 – 16.30: *Panel discussion – barriers and research agenda*

Moderator: MARJOT Thomas, MEHTA Gautam

Panel: MEHTA Gautam, HANSEN Camilla Dalby, ASKGAARD Gro, VERGIS Nikhil

16.30 – 17.00: Closing remarks, KRAG Aleksander

19.00: Dinner

June 24 – Wrap-up and Departure

09.00 – 11.00: The road ahead: Summary and wrap-up

09.00 - 10.30: *ALCOMET 2026 Road Map paper – Summaries of key barriers and research agenda*, Chairs of the Road Map paper working groups

10.30 – 10.45: *Feedback*, HANSEN Johanne Kragh

10.45 – 11.00: *Closing remarks*, KRAG Aleksander

11.00: Official Close of the Meeting and Departures
